Thioredoxin, thioredoxin reductase and tumour necrosis factor-α expression in melanoma cells: Correlation to resistance against cytotoxic attack

Melanoma Research

Volumn 10, Issue 4, 2000, Pages 331-343

  Barral, A M ^a   Kallstrom R ^a   Sander, B ^b   Rosen A ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antioxidants; Cytokines; Melanoma; Redox regulation; Thioredoxin; Thioredoxin reductase; TNF

Indexed keywords

THIOREDOXIN; THIOREDOXIN REDUCTASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RESISTANCE; CELL CULTURE; CELL PROTECTION; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; MELANOMA; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

CELL SURVIVAL; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; INTERLEUKINS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA; MICROSCOPY, CONFOCAL; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 0033818271     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200008000-00004     Document Type: Article

References (68)

1. Cancer tumor antigens
2. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines
3. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas
4. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression
5. Tumor necrosis factor-alpha expression in human primary malignant melanoma and it relationship to tumor infiltration by CD3+ cells
6. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions
7. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
8. Thioredox- in prolongs survival of B-type chronic lymphocytic leukemia cells
9. Redox regulation of cellular activation
10. Thioredoxin as a potent costimulus of cytokine expression
11. Role of sulfhydryl groups in induction of cell surface down-modulation and shedding of extracellular domain of human TNF receptors in human histiocytic lymphoma U937 cells
12. Thioredoxin
13. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity
14. Redox signalling and the control of cell growth and death
15. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells
16. Thioredoxin reductase activity at the surface of human primary cutaneous melanomas and their surrounding skin
17. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62
18. Involvement of thioredoxin in rheumatoid arthritis: Its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts
19. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines
20. Variable expression of tumor necrosis factor alpha in human malignant melanoma localized by in situ hybridization for mRNA
21. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure
22. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines
23. Secretion of thioredoxin after in vitro activation of human B cells
24. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells
25. The role of thioredoxin reductase in the reduction of free radicals at the surface of the epidermis
26. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia
27. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and transformed cells: Presence in human plasma
28. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes
29. Production of cytokines by human melanoma cells and melanocytes
30. Cytokine expression in human primary and metastatic melanoma cells: Analysis in fresh bioptic specimens
31. Interleukin-1 production in tumor cells of human melanoma surgical specimens
32. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immuno-reactivities in human common and dysplastic nevocellular nevi and malignant melanoma
33. Effect of interferon-alpha on the expression of tumour necrosis factor-alpha by metastatic malignant melanoma in vivo
34. Immunohistological and immunoelectron microscopic identification of TNF alpha in normal human and murine epidermis
35. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact
36. Human keratinocytes are a source for tumor necrosis factor alpha: Evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light
37. Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells
38. Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN gamma
39. Tumor necrosis factor is delivered to mitochondria where a tumor necrosis factor-binding protein is localized
40. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells
41. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells
42. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1
43. TNF-alpha-mediated apoptosis is initiated in caveolae-like domains
44. Production of multiple cytokines by cultured human melanomas
45. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses
46. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops
47. Continuous autotropic signaling by membrane-expressed tumor necrosis factor
48. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor
49. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis
50. Modulation of surface TNF expression by human leukaemic cells alters their sensitivity to exogenous TNF
51. Induction of unresponsiveness to tumor necrosis factor (TNF) after autocrine TNF expression requires TNF membrane retention
52. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide
53. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines
54. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin
55. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells
56. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha
57. TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase
58. Increased sensitivity to peroxidizing agents is correlated with an imbalance of antioxidants in normal melanocytes from melanoma patients
59. Enhanced synthesis of tumor necrosis factor-inducible proteins, plasminogen activator inhibitor-2, manganese superoxide dismutase, and protein 28/5.6, is selectively triggered by the 55-kDa tumor necrosis factor receptor in human melanoma cells
60. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1
61. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases
62. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling
63. Recent advances in the molecular basis of TNF signal transduction
64. Role of redox potential and reactive oxygen species in stress signaling
65. Gene expression and the thiol redox state
66. From receptors to stress-activated MAP kinases
67. Thioredoxin expression and localization in human cell lines: Detection of full-length and truncated species
68. Monoclonal antibodies to human thioredoxin reductase